Dicerna Pharmaceutic (DRNA) 3.14 $DRNA Dicerna

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dicerna Pharmaceutic (DRNA) 3.14 $DRNA

Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 7.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 7:25AM CDT
Dicerna Pharmaceuticals, Inc. (DRNA) was a moved big last session, as its shares jumped over 7% on the day.
DRNA: 3.14 (+0.01), GERN: 2.75 (+0.02)

Dicerna Reports Second Quarter 2016 Financial and Operational Results
BusinessWire - Thu Aug 04, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the second quarter ended June 30, 2016.
DRNA: 3.14 (+0.01)

Dicerna to Report Second Quarter 2016 Financial Results and Host Conference Call on August 4, 2016
BusinessWire - Thu Jul 28, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2016 financial results after market close on Thursday, August 4, 2016.
DRNA: 3.14 (+0.01)

Dicerna Appoints Martin Freed, M.D., to Board of Directors
BusinessWire - Wed Jun 15, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of Martin Freed, M.D., former co-founder and chief medical officer of Civitas Therapeutics, Inc., to its board of directors. The appointment will be effective immediately, and increases the size of Dicerna's board of directors to eight members. The board of directors determined Dr. Freed is an independent director.
DRNA: 3.14 (+0.01), CVTS: ()

Dicerna to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference. The presentation will take place on Thursday, June 9, 2016 at 1:30 p.m. ET at the Grand Hyatt in New York City.
DRNA: 3.14 (+0.01)

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
BusinessWire - Fri May 13, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1). A severe, rare, inherited disorder of the liver, PH1 often results in kidney failure, and there are no approved therapies for the disease.
DRNA: 3.14 (+0.01)

Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates
BusinessWire - Wed May 11, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) injection, with potential utility against multiple therapeutic targets. The presentation will take place at the 18th Annual TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Long Beach, Calif.
DRNA: 3.14 (+0.01)

Dicerna Reports First Quarter 2016 Financial and Operational Results
BusinessWire - Mon May 09, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016.
DRNA: 3.14 (+0.01)

Dicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016
BusinessWire - Mon May 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2016 financial results after market close on Monday, May 9, 2016.
DRNA: 3.14 (+0.01)

Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer
BusinessWire - Mon Apr 18, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr. Green has served as the Company's interim CFO since January 2016.
DRNA: 3.14 (+0.01)

Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.74 (+0.06), DRNA: 3.14 (+0.01), INCY: 82.02 (+1.21), LLY: 76.85 (-0.38), STML: 8.03 (-0.12), SNTA: 0.34 (+0.07), ANTH: 2.93 (+0.02), EXEL: 11.54 (+0.19)

Dicerna to Present at the 2016 Leerink Partners Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference. The presentation will take place at the Waldorf Astoria in New York City on Thursday, February 11th, 2016 at 11:35 a.m. ET.
DRNA: 3.14 (+0.01)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Dec 31, 3:27PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on December 31, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 115,000 shares of common stock to two new employees, with a grant date of December 31, 2015 (the "Q4 2015 Inducement Grants" .
DRNA: 3.14 (+0.01)

Alnylam Submits Clinical Trial Application for ALN-GO1 in UK
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 2:50PM CST
Alnylam (ALNY) filed a CTA for ALN-GO1 with the UK Medicines and Healthcare products Regulatory Agency for the treatment of primary hyperoxaluria type 1.
DRNA: 3.14 (+0.01), ALNY: 69.17 (+0.15), ANIK: 47.89 (-0.05), SNY: 39.18 (+0.77)

Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
BusinessWire - Mon Dec 21, 3:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the clinical development of DCR-MYC, Dicerna's investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic designed to silence MYC, an oncogene implicated in multiple tumor types. Dicerna plans to report proof-of-concept data for DCR-MYC in the second half of 2016 based on anticipated results from a Phase 1 clinical trial of DCR-MYC in patients with advanced solid tumors, multiple myeloma, or lymphoma, and a Phase 1b/2 trial in patients with hepatocellular carcinoma (HCC).
DRNA: 3.14 (+0.01)

Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers
BusinessWire - Mon Dec 21, 3:10PM CST
--- Ongoing Observational Study Measures Biomarkers Implicated in the Pathogenesis of PH1 -
DRNA: 3.14 (+0.01)

Dicerna Announces Addition to NASDAQ Biotechnology Index
BusinessWire - Wed Dec 16, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December 21, 2015.
DRNA: 3.14 (+0.01)

Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer
BusinessWire - Tue Dec 15, 5:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John "Jack" Green as interim chief financial officer (CFO), effective January 1, 2016. He replaces James Dentzer, whose departure is also announced today.
VSTM: 1.33 (-0.01), DRNA: 3.14 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 55

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading

Top 5 Most Recently Viewed Articles

GoldHaven Resources Expands Exploration Amid Robust Gold Prices

Updated Category News Views 299

Gold's Resilience Fuels Growth Initiatives Gold prices have steadily stabilized above $4,200 per ounce, prompting renewed interest among investors seeking safe-haven assets. This robust price environment encourages extensive drilling programs aimed at expanding resource bases. GoldHaven Resources Corp. (CSE: GOH) is at the forefront of this momentum, actively advancing...

Continue Reading
HSBC Highlights Reliance Industries' Growth Potential and Strategy

Updated Category News Views 287

HSBC Upgrades Reliance Industries Stock Target Recently, HSBC raised its price target for Reliance Industries (RIL:IN) from INR 2,780.00 to INR 3,010.00 while maintaining a Hold rating. This revision reflects a promising outlook on the company's comprehensive business structure and financial standing. Core Sectors Driving Performance HSBC's analysts highlighted Reliance's...

Continue Reading
Vallourec's Strategic Move: Partial Redemption of Notes

Updated Category News Views 142

Vallourec's Strategic Financial Maneuver Vallourec, an industry leader in premium tubular solutions, has made a significant announcement regarding its senior notes due 2032. This decision is part of its ongoing strategy to enhance its financial stability and market position. Details of the Partial Redemption The company plans to redeem $82 million of its senior notes,...

Continue Reading
Health Assurance Foundation Teams Up to Enhance Healthcare Access

Updated Category News Views 80

The Health Assurance Foundation officially launched as a nonprofit back in 2024, focusing on strengthening the healthcare system by investing in local communities. Its mission? Making healthcare more equitable and accessible for everyone. Sounds good on paper, right? But when you peel back the layers, things get murky. Community Health Worker Initiative: Is It Enough? The...

Continue Reading
Market Pay Unveils Seamless POS Solution for Merchants Across Europe

Updated Category News Views 208

Market Pay Launches a Game-Changing Payment Solution The French fintech company Market Pay, a prominent player in the European payment processing field, is excited to unveil its new point-of-sale software payment solution. This innovative app integrates both terminal and smartphone payment options into a single, user-friendly platform. This development not only simplifies...

Continue Reading